1302 On Other Exchanges
1302 is not on other exchanges.

lifetech scientific corp (1302) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LIFETECH SCIENTIFIC CORP (1302)

Related News

No related news articles were found.

lifetech scientific corp (1302) Related Businessweek News

No Related Businessweek News Found

lifetech scientific corp (1302) Details

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders worldwide. The company operates through Congenital Heart Diseases Business, Peripheral Vascular Diseases Business, and Surgical Vascular Repair Business segments. Its products include HeartR, Cera, and CeraFlex congenital heart defect occluders; Ankura TAA and abdominal aortic aneurysm stent graft systems; delivery systems, such as FuStar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; SeQure snare systems; and bioprosthetic heart valves. The company is also involved in the trading of medical devices. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People’s Republic of China.

611 Employees
Last Reported Date: 08/26/16
Founded in 1999

lifetech scientific corp (1302) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: CNY1.3M
Chief Financial Officer, Secretary and Execut...
Total Annual Compensation: CNY2.0M
Compensation as of Fiscal Year 2015.

lifetech scientific corp (1302) Key Developments

Lifetech Scientific Corporation Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016

Lifetech Scientific Corporation announced unaudited consolidated earnings results for the six months ended June 30, 2016. For the six months, the company announced revenue of RMB 156,221,000 compared to RMB 149,142,000 for the same period a year ago. Operating profit was RMB 58,058,000 compared to RMB 52,363,000 for the same period a year ago. Profit before tax was RMB 63,145,000 compared to loss of RMB 190,384,000 for the same period a year ago. Profit for the period attributable to owners of the company was RMB 51,870,000 compared to loss of RMB 202,172,000 for the same period a year ago. Earnings per share, basic and diluted was RMB 0.011 compared to loss of RMB 0.051 for the same period a year ago. Net cash generated from operating activities was RMB 13,439,000 compared to RMB 42,829,000 for the same period a year ago. Expenditure incurred and capitalized as intangible assets was RMB 11,505,000 compared to RMB 11,066,000 for the same period a year ago. Deposits paid for and purchase of property, plant and equipment was RMB 44,572,000 compared to RMB 37,303,000 for the same period a year ago.

LifeTech Scientific Corporation Received Approval from the China Food and Drug Administration

The board of directors of LifeTech Scientific Corporation announced that on August 19, 2016, a notice has been received from the China Food and Drug Administration formally approving the Group's application of the innovative medical device status, which is also known as the 'CFDA green channel', for the Group's products namely, the HeartTone pacemaker, and the IrisFIT patent foramen ovale occluder in accordance with CFDA's Procedures for Special Approval of Innovative Medical Devices (Trial) No. 13 (2014). Given the Status has been approved, the CFDA will provide additional support and assistance to the Group for the registration of the Products. In particular, the Center for Medical Device Evaluation of the CFDA will designate an officer for communications and discussions on the technical issues with the Group and priority will be given by the CFDA to the Products for their technical review and subsequent registration approval in future. In addition, the relevant medical device testing institution shall, upon receipt of the samples of the Products, prioritise the medical device registration tests of the Products and then issue their respective test reports. The Status will accelerate the registration procedures of the Products in the People's Republic of China.

LifeTech Scientific Corporation to Report First Half, 2016 Results on Aug 26, 2016

LifeTech Scientific Corporation announced that they will report first half, 2016 results on Aug 26, 2016


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1302 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1302.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1302 Industry Range
Price/Earnings 25.9x
Price/Sales 20.0x
Price/Book 25.8x
Price/Cash Flow 24.9x
TEV/Sales 17.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact LIFETECH SCIENTIFIC CORP, please visit www.lifetechmed.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.